You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Our Medicines

GSK × ViiV remains committed to developing and investing in new medicines and innovations that aim to improve the treatment success and quality of life of all people living with HIV.

Dovato logo

DOVATO (dolutegravir/lamivudine)

DOVATO is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.1

SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET

Learn more about Dovato

 





 

Vocabria+Rekambys logo

VOCABRIA▼ (Cabotegravir) & REKAMBYS▼ (Rilpivirine)

Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.2,3

ABBREVIATED PRESCRIBING INFORMATION

REKAMBYS PATIENT INFORMATION LEAFLET

VOCABRIA PATIENT INFORMATION LEAFLET

Learn more about Vocabria & Rekambys

Juluca logo

JULUCA (dolutegravir/rilpivirine)

JULUCA is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable ARV regimen for ≥6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.4

SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET










 

Triumeq logo

TRIUMEQ (dolutegravir/abacavir/
lamivudine)

Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.5

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patient known to carry the HLA-B*5701 allele.5

INFORMATION ON ABACAVIR HYPERSENSITIVITY REACTION

SUMMARY OF PRODUCT CHARACTERISTICS

PATIENT INFORMATION LEAFLET

Tivicay logo

TIVICAY (dolutegravir)

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.6

TIVICAY10/25/50MG SUMMARY OF PRODUCT CHARACTERISTICS

TIVICAY10/25/50MG PATIENT INFORMATION LEAFLET

TIVICAY 5MG SUMMARY OF PRODUCT CHARACTERISTICS

TIVICAY 5MG PATIENT INFORMATION LEAFLET






 

References

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor.

©2024 GSK group of companies. All rights reserved.

Date of preparation: February 2024 | PM-IE-HVX-WCNT-190009